Status: Recruiting Patients
A Phase 1b trial entitled CAPRA (CAvatak and PembRolizumab in Advanced Melanoma) to investigate the use of CAVATAK® in combination with pembrolizumab (KeytrudaTM) in patients with advanced melanoma is underway at Rutgers Cancer Institute in New Brunswick, New Jersey.
The trial is designed to evaluate the safety and tolerability of the established dose of intratumoural CAVATAK in combination with pembrolizumab in 30 patients with advanced melanoma for whom pembrolizumab would be considered the standard of care.
Investigators will also assess evidence of anti-cancer activity, including response rates and bio-markers of anti-tumour immunity.
For further information about this trial, please visit the Clinical Trial website at: ClinicalTrials.gov Identifier: NCT02565992